IMPORTANCE Intensive lifestyle interventions focused on diet and exercise can reduce weight and improve diabetes management. However, the long-term effects on health care use and spending are unclear, especially for public payers.

OBJECTIVE To estimate the association of effective intensive lifestyle intervention for weight loss with long-term health care use and Medicare spending.

DESIGN, SETTING, AND PARTICIPANTS This ancillary study used data from the Look AHEAD randomized clinical trial, which randomized participants with type 2 diabetes to an intensive lifestyle intervention or control group (ie, diabetes support and education), provided ongoing intervention from 2001 to 2012, and demonstrated improved diabetes management and reduced health care costs during the intervention. This study compared Medicare data between study arms from 2012 to 2015 to determine whether the intervention was associated with persistent reductions in health care spending.

EXPOSURE Starting in 2001, Look AHEAD's intervention group participated in sessions with lifestyle counselors, dieticians, exercise specialists, and behavioral therapists with the goal of reducing weight 7% in the first year. Sessions occurred weekly in the first 6 months of the intervention and decreased over the intervention period. The controls participated in periodic group education sessions that occurred 3 times per year in the first year and decreased to 1 time per year later in the trial.

MAIN OUTCOMES AND MEASURES Outcomes included total Medicare spending, Part D prescription drug costs, Part A and Part B Medicare spending, hospital admissions, emergency department visits, and disability-related Medicare eligibility.

RESULTS This study matched Medicare administrative records for 2796 Look AHEAD study participants (54% of 5145 participants initially randomized and 86% of 3246 participants consenting to linkages). Linked intervention and control participants were of a similar age (mean [SD] age, 59.6 [5.4] years vs 59.6 [5.5] years at randomization) and sex (818 [58.1%] women vs 822 [59.3%] women). There was no statistically significant difference in total Medicare spending between groups (difference, −$133 [95% CI, −$1946 to $1681]; P = .89). In the intervention group, compared with the control group, there was statistically significantly higher Part B spending (difference, $513 [95% CI, $70 to $955]; P = .02) but lower prescription drug costs (difference, −$803 [95% CI, −$1522 to −$83]; P = .03).

(continued)
CONCLUSIONS AND RELEVANCE  This ancillary study of a randomized clinical trial found that reductions in health care use and spending associated with an intensive lifestyle intervention for type 2 diabetes diminished as participants aged. Intensive lifestyle interventions may need to be sustained to reduce long-term health care spending.

TRIAL REGISTRATION  ClinicalTrials.gov Identifier: NCT03952728

Introduction

About 9% of the US population has received a diabetes diagnosis, and treatment costs exceed $327 billion per year.1 Most of this diabetes is type 2, and primary and secondary prevention are cornerstones of the public health strategy.2 In particular, excess body weight is linked with worse glycemic control and elevated cardiovascular risk.3 As a result, there is significant interest in intensive lifestyle management with a focus on diet, physical activity, and weight loss to reduce the incidence and harm of type 2 diabetes.4 There are reasons to be optimistic. Individualized guidance on diet and exercise are effective at preventing diabetes in the first place and improving diabetes control and reducing cardiovascular risk factors for those with type 2 diabetes.5–8

Policy makers, insurers, and employers have taken notice. Versions of intensive lifestyle interventions (ILIs) have been incorporated into Medicare,9 workplace wellness programs,10 and patient-centered medical homes.11 However, these interventions are labor intensive and expensive, often involving lifestyle counselors, exercise specialists, diététiciens, and administrative staff.12,13 Thus, it is important to demonstrate long-term efficacy and value, although some advocates assume it.14 Many studies find that interventions can reduce short-term health care use, but long-term estimates on health care use and costs often rely on simulations that make assumptions about long-term persistence of these short-term effects.15,16

In this study, we linked administrative data with a clinical trial to examine whether reductions in health care spending were sustained after an ILI ended. The data were obtained from the Look AHEAD (Action for Health in Diabetes) study, one of the largest ILIs performed to date. Beginning in 2001, 5145 patients aged 45 to 76 years with type 2 diabetes who were overweight or obese were randomized to ILI or to a control group that received diabetes support and education.8 Although the intervention did not significantly reduce its primary outcome, a composite of death from cardiovascular causes, nonfatal myocardial infarction or stroke, or hospitalization for angina, the intervention successfully reduced participants’ weight, increased physical fitness and functional status, lowered hemoglobin A1c (HbA1c), and increased probability of diabetes remission, among other clinical benefits.8,17–20 However, the intervention was also expensive, costing $2865 per patient per year in the first year and gradually decreasing to $1120 per patient per year in years 5 to 9 (in 2012 dollars), whereas the diabetes support and education received by the control group cost less than $202 per patient per year in the first year and $103 in years 5 to 9.13 The intervention also reduced hospitalizations, prescription drug use, and total health care costs during the intervention period by $5280 per patient (in 2012 dollars).21 An outstanding question is whether these reductions persisted after the intervention, particularly given that the intervention was not cost-saving during the trial.
Methods

Study Overview and Design
This ancillary study to the Look AHEAD randomized clinical trial examines the association of an ILI for weight loss targeted to patients with type 2 diabetes with long-term health care use, Medicare spending, and disability insurance enrollment. The Look AHEAD study ended the intervention in September 2012 but continued to follow participants. As a part of the observational studies following the intervention period, the Look AHEAD study obtained written informed consent to perform linkages with administrative records. We linked study participants to Medicare records (for those who consented to such a linkage) to estimate outcomes in the year the intervention ended (2012) and the 3 following years (2013 to 2015). The University of Southern California and Wake Forest institutional review boards approved the data linkage, and the University of Minnesota institutional review board deemed it exempt from review because University of Minnesota researchers did not work with direct identifiers. Our manuscript proposal to the Look AHEAD study, including our proposed outcome measures and analyses, is available in the Manuscript Proposal Supplement 1. The trial protocol for the Look AHEAD study is published elsewhere.8 This study is reported following Consolidated Standards of Reporting Trials (CONSORT) reporting guideline, as applicable to a secondary analysis of clinical trial data.

The Look AHEAD study randomized participants within 16 study sites to either the ILI group or a control group (diabetes support and education). Randomization occurred between 2001 and 2004. The most intensive portion of the intervention, and the greatest weight loss, occurred during the first year, when participants had weekly sessions with counselors, dieticians, exercise specialists, and behavioral health staff. By the fourth year, individual contacts occurred on a monthly basis, as well as group classes provided throughout the year.8 The control group received 3 educational sessions per year in the first 4 years, and annually thereafter.

Data Linkage and Study Population
Our analysis compared Medicare outcomes between the ILI and control groups after the intervention. Not all study participants were given the opportunity to consent to data linkages, as the queries were conducted as part of 2 cohort studies following the intervention (the Look AHEAD-Continuation study and the Look AHEAD-Extension study). Of the original 5145 Look AHEAD participants, 3753 (1907 intervention and 1846 controls) participated in the Look AHEAD Continuation or Extension studies (Figure 1). Of these, 3246 participants (1648 intervention participants and 1598 control participants) consented to administrative data linkages and 2796 participants (1409 intervention participants and 1387 control participants) were successfully linked to Medicare data (comprising 75% of participants in the Continuation and Extension studies and 86% of participants consenting to linkages). More details of the linkage are available in the eAppendix in Supplement 2.

Data Sources
We used the Medicare Master Beneficiary Summary File to determine participants' eligibility, Medicare Advantage enrollment, and spending by service category. One concern about analyses using Medicare data is the absence of claims data for participants in Medicare Advantage. We measured hospital admissions and emergency department (ED) use for enrollees in Medicare Advantage using patient-level data from the 2012 to 2014 Healthcare Effectiveness Data and Information Set. Medicare Advantage plans are required to report these data to the National Committee for Quality Assurance for nearly all Medicare Advantage enrollees; thus, these data capture health care use for most enrollees in our sample. We constructed identical measures of hospitalizations and ED visits for fee-for-service Medicare enrollees from Medicare claims, following prior research comparing fee-for-service Medicare and Medicare Advantage.22 We linked the
Medicare data with Look AHEAD trial data, which includes baseline participant characteristics, intervention arm assignment, and clinical outcomes during the study.

**Study Measures**

We examined the long-term associations of the ILI with measures of health care use, medical care spending, prescription drug spending, and Medicare eligibility owing to disability or end-stage renal disease. We preregistered our study outcomes on ClinicalTrials.gov.

The unit of observation for all health care use and spending measures was at the person-year level. Measures of health care use included whether participants had any hospital admission or ED visit and the number of hospitalizations and ED visits. Annual medical care spending measures included Medicare Part A (hospitals, postacute care, and other health care facilities) and Part B (professional payments, some home health care, medical equipment, laboratory tests, mental health services, and ambulance services). We measured annual prescription drug spending using total drug costs incurred in Medicare Part D. Specifically, this outcome measures total Part D drug costs for a given year, including the ingredient cost, dispensing fees and sales tax, but not manufacturer discounts or rebates.23 We also investigated annual beneficiary out-of-pocket spending on prescription drugs in Medicare Part D. Total annual Medicare spending was defined as the sum of Medicare Part A and Part B spending and total Part D prescription drug costs. Functional status was measured using the reason for initial Medicare eligibility, reflecting that individuals who are eligible for Social Security Disability Insurance become eligible for Medicare after 2 years.24 In addition, individuals with end-stage renal disease, which can be a complication of type 2 diabetes, may be eligible for Medicare prior to age 65 years. A small minority of participants were enrolled in Medicare at the beginning of the trial. Thus, to the extent that the ILI improved functional status or reduced diabetes-related kidney disease, the trial could have decreased subsequent Medicare eligibility owing to disability or end-stage renal disease and increased Medicare enrollment owing to age.

A key challenge in our analysis was that not all components of health care spending were available for all study participants, based on enrollment in traditional Medicare vs Medicare Advantage and enrollment in Part D drug coverage. Specifically, annual medical care spending measures (excluding prescription drugs) were only available for fee-for-service Medicare enrollees.

---

**Figure 1. Flow Diagram of Look AHEAD Participants in Sample**

3753 Individuals in Look AHEAD Continuation or Extension (starting 2012)

1907 From intensive lifestyle intervention

1846 From control group

258 No consent for link

1648 Consented to administrative data link

159 No match for ID

88 No enrollment (pre-2016)

1409 Linked to Medicare data

1333 With hospitalization outcomes

1024 With prescription drug outcomes

856 With Part A and Part B fee-for-service spending

561 With Parts A, B, and D spending

1387 With Medicare eligibility due to disability

1304 With hospitalization outcomes

1007 With prescription drug outcomes

853 With Part A and Part B fee-for-service spending

553 With Parts A, B, and D spending

127 No match for ID

84 No enrollment (pre-2016)
(ie, those enrolled in Medicare Parts A and B), and prescription drug costs were only available for enrollees in Medicare Part D prescription drug coverage. Consequently, total annual Medicare spending (ie, the sum of medical care spending and prescription drug costs) was only available for linked Look AHEAD participants enrolled in both fee-for-service Medicare and Medicare Part D.

As a result, in our primary analysis, we estimated the association of ILI with health care use and spending measures for individuals enrolled in fee-for-service Medicare (Parts A and B) and Part D prescription drug coverage. For this sample, we were able to observe total Medicare spending, as well as each component of Medicare spending and health care use. Notably, the probability of inclusion in the primary analysis sample was nearly identical between ILI and control group person-years (1662 person-years [31.0%] vs 1592 person-years [30.3%]; P for difference = .43) and included 3254 person-years between 2012 and 2015 (for spending measures) and 2327 person-years between 2012 and 2014 (for health care use measures). Thus, while this sample comprised a minority of linked participants, inclusion in this group appeared unrelated to intervention status and the sample offered sufficient statistical power to detect meaningful effects.

Next, we investigated whether the effects of ILI for the primary analysis sample were representative of the broader linked sample by estimating analyses using the largest possible sample for each component of health care use and Medicare spending. For hospital admissions and ED visits, this analysis included 3705 linked person-years (95%) in the control group and 3792 linked person-years (96%) in the ILI group (P for difference = .46) (eTable 1 in Supplement 2). For prescription drug costs, the sample included all participants enrolled in Medicare Part D, comprising 3463 linked person-years (66%) in the control group and 3594 linked person-years (67%) in the ILI group (P = .22). Finally, for Part A and Part B spending, our sample included 2824 person-years (54%) in the control group and 2874 person-years (54%) in the ILI group (P = .89).

Statistical Analysis
First, we examined whether our linked sample (ie, those who consented and for whom we were able to successfully obtain Medicare records) was representative of the broader Look AHEAD study. We compared the characteristics of the linked sample (2796 participants) with originally randomized participants (5145 participants) and then assessed whether the linked sample replicates the effects of ILI on weight and HbA1c documented for the original sample.8

Next, we estimated the associations of ILI with hospital and ED use and Medicare spending. We used generalized linear models for health care use and spending outcomes (eAppendix in Supplement 2).25 We used logit models to estimate Medicare disability status and other binary outcomes. For the person-year-level analysis of annual health care use and spending, we calculated cluster-robust SEs at the person level. We calculated heteroskedasticity-robust SEs for the person-level disability analysis. All analyses controlled for demographic characteristics (ie, age, sex, and self-reported race/ethnicity), clinical status at initial randomization (ie, obesity status, HbA1c, hypertension, and cardiovascular disease), socioeconomic status at initial randomization (ie, education and income), and initial study site (using fixed effects). We also controlled for months of Medicare coverage for those who may have enrolled mid-year and year-fixed effects in models investigating health care use and Medicare spending.

We also estimated year-specific associations of the intervention with selected measures of health care use and spending.

Data were analyzed using Stata statistical software version 15.0 (StataCorp). P values were 2-sided, and statistical significance was set at .05. Analysis began in December 2018 and was completed in September 2020.

Results
We found no statistically significant differences in baseline characteristics between linked ILI and control group participants (Table 1). The 1409 ILI and 1387 control participants were of a similar age
Associations of ILI With Weight and HbA1c During and After the Trial

We found similar associations of ILI with weight and HbA1c for the linked sample compared with the full Look AHEAD study during and after the trial (Figure 2).26 During our sample period from 2012 to 2015, the linked ILI group continued to have lower weight than the control group (adjusted difference: −1.9% [95% CI, −2.6% to −1.2%]) of initial body weight, P < .001). However, there was no significant difference in HbA1c between 2012 and 2015. These results are discussed in more detail in the eAppendix in Supplement 2.

Associations of ILI With Health Care Use and Spending

For our primary analysis sample (ie, fee-for-service Medicare enrollees with Part D prescription drug coverage), a similar percentage of person-years in the ILI and control groups had any hospitalization (188 person-years [15.8%] vs 174 person-years [15.3%]; adjusted difference: 0.1 [95% CI, −3.2 to 3.3] percentage points; P = .96) and any ED visit (285 person-years [23.9%] vs 234 person-years [20.6%]; adjusted difference: 3.5 [95% CI, −0.3 to 7.2] percentage points; P = .07) (Table 2). Similarly, there was no difference in the annual number of hospital admissions or the annual number of ED visits. We found no significant difference in Part A spending (adjusted difference: $488 [95% CI, −$715 to $1691]; P = .43) but found higher Part B spending for the ILI group (adjusted difference: $513 [95% CI, $70 to $955]; P = .02). We found that ILI participants had lower mean (SD) Part D prescription drug costs compared with the control group ($5046 [$8199] vs $5849 [$9122];

Table 1. Baseline Characteristics of Linked Participants

| Characteristic                                      | No. (%) |                             |                             |
|-----------------------------------------------------|---------|-----------------------------|-----------------------------|
|                                                     | Control (n = 1387) | Intervention (n = 1409)    |
| Age, mean (SD) y                                    | 59.6 (5.5) | 59.6 (5.4)                  |
| Women                                               | 822 (59.3) | 818 (58.1)                  |
| Race/ethnicity                                      | 915 (66.0) | 938 (66.6)                  |
| White, non-Hispanic                                 | 234 (16.9) | 227 (16.1)                  |
| Black, non-Hispanic                                 | 195 (14.1) | 188 (13.3)                  |
| Hispanic                                            | 100.3 (18.1) | 100.1 (19.1)                |
| BMI, mean (SD), kg                                  | 35.8 (5.7) | 35.6 (5.9)                  |
| Obesity status                                      | 200 (14.4) | 225 (16.0)                  |
| Reference range to overweight                       | 896 (64.6) | 901 (63.9)                  |
| Obese                                               | 291 (21.0) | 283 (20.1)                  |
| Hemoglobin A1c, % of total hemoglobin               | 7.2 (1.1)  | 7.2 (1.1)                   |
| Duration of diabetes, mean (SD) y                   | 6.6 (5.9)  | 6.8 (6.8)                   |
| Hypertension                                        | 1169 (84.3) | 1173 (83.3)                 |
| History of cardiovascular disease                   | 169 (12.2) | 178 (12.6)                  |
| Employed                                            | 916 (66.0) | 891 (63.2)                  |
| Education                                           | 304 (21.9) | 297 (21.1)                  |
| ≥High school                                        | 510 (36.8) | 479 (34.0)                  |
| Some postsecondary                                  | 573 (41.3) | 633 (44.9)                  |

Abbreviation: BMI, body mass index (calculated as weight in kilograms divided by height in meters squared).
SI conversion factor: To convert hemoglobin A1c to proportion of total hemoglobin, multiply by 0.01.
adjusted difference: −$803 [95% CI, −$1522 to −$83]; P = .03) and lower mean (SD) Part D out-of-pocket spending ($1353 [$2197] vs $1536 [$1891]; adjusted difference: −$196 [95% CI, −$383 to −$8]; P = .04). However, there was no difference in mean (SD) total Medicare spending ($15 005 [$23 522] vs $15 096 [$21 821]; adjusted difference: −$133 [95% CI, −$1946 to $1681]; P = .89). We also estimated year-specific ILI vs control group differences in the probability of hospital admission and ED visits, Part D prescription drug costs, and total Medicare spending. We displayed each outcome by year and intervention status, adjusting for baseline characteristics and study site (Figure 3). None of the year-specific adjusted outcomes differed significantly by intervention status. The only statistically significant year-specific differences were for Part D costs in 2012 (adjusted difference for ILI versus control group: −$836.6 [95% CI, −$1517.7 to −$155.6]; P = .02) and 2013 (adjusted difference: −$785.6 [95% CI, −$1529.9 to −$41.3]; P = .04), which became insignificant in subsequent years.

In ancillary analyses, we estimated differences in each component of health care use and spending between the ILI and control groups using the largest samples possible for each measure (eTable 3 in Supplement 2). Similar to the primary analysis sample, we found no difference in hospital admissions, ED visits, and Part A spending; we found lower Part D prescription drug costs (adjusted difference: −$538 [95% CI, −$993 to −$83]; P = .02) and Part D beneficiary out-of-pocket drug spending (adjusted difference: −$171 [95% CI, −$282 to −$60]; P = .002). In contrast to the primary sample, we found no significant difference in Part B spending. Finally, there was no difference in the proportion of ILI and control group participants who were originally eligible for Medicare because of end-stage renal disease or Social Security Disability Insurance enrollment (150 participants [10.7%] vs 142 participants [10.3%]; adjusted difference: 0.3 [95% CI, −1.7 to 2.4] percentage points; P = .77).
Discussion

In an era of increasing health care costs associated with chronic illness, it is imperative to identify interventions to reduce long-term spending without harming patient care. To this end, this ancillary study linked data from a large randomized clinical trial to Medicare claims to identify the long-term associations of intensive lifestyle management for patients with type 2 diabetes. Similar to the overall study, we found significant reductions in weight and HbA1c in the linked intervention group compared with the linked control group, with reductions in weight persisting beyond the intervention period. Despite this, we found no postintervention differences in hospital admissions or ED use, Medicare Part A spending, or eligibility for Medicare owing to enrollment in Social Security Disability Insurance or end-stage renal disease. While we found that the intervention participants had lower gross costs for Part D drugs from 2012 to 2015, they also had higher Part B spending, and there was no difference in total Medicare spending.

Our study is not the first to investigate whether improving diabetes management can reduce health care spending. Observational studies have found that reductions in body mass index and HbA1c were correlated with reductions in health care spending among patients with type 2 diabetes. Other studies have found that interventions successfully managing diabetes were associated with reduced short-term health care spending. However, we found that the benefits of successful diabetes interventions may not persist after interventions end. Notably, our ability to track health care use and spending was facilitated by the linkage of trial participants with Medicare data and highlights the utility of administrative data sources for tracking the long-term associations of interventions with patient outcomes.

Our results are also related to recent work using randomized clinical trials to estimate the associations of workplace wellness programs with health care use and spending. These programs include components that are similar to the intensive lifestyle intervention we studied, with registered dieticians and other practitioners providing counseling on nutrition and physical activity. In contrast, the wellness programs were targeted broadly at all employees, and both studies found small and statistically insignificant associations of the programs with health outcomes, health care use, and spending. Our results, paired with earlier estimates from the Look AHEAD trial, show that targeting lifestyle interventions to at-risk populations (ie, patients with type 2 diabetes) may be

### Table 2. Health Care Use and Spending by Group

| Outcome | Group          | Adjusted difference (95% CI) | Difference, % (95% CI)b | P value |
|---------|----------------|------------------------------|-------------------------|---------|
|         | Control | Intervention |                          |          |
| Hospital and emergency department use (2012-2014) | | | | |
| Any hospital admission, No. (%) | 174 (15.3) | 188 (15.8) | 0.1 (−3.2 to 3.3) | 0.5 (−20.6 to 21.7) | .96 |
| Hospital admissions per participant-year, mean (SD) | 0.22 (0.65) | 0.22 (0.63) | −0.01 (−0.07 to 0.05) | −1.9 (−30.2 to 22.4) | .77 |
| Any ED visit, No. % | 234 (20.6) | 285 (23.9) | 3.5 (−0.3 to 7.2) | 16.9 (−1.2 to 35.0) | .07 |
| ED visits per participant-year, mean (SD) | 0.29 (0.75) | 0.32 (0.66) | 0.03 (−0.04 to 0.09) | 9.2 (−13.5 to 31.8) | .43 |
| Medicare spending (2012-2015), mean (SD) | | | | |
| FFS spending | | | | |
| Part A | 5529 (16,152) | 5687 (15,183) | 488 (−715 to 1691) | 8.8 (−12.9 to 30.6) | .43 |
| Part B | 3717 (4593) | 4273 (7824) | 513 (70 to 955) | 13.8 (1.9 to 25.7) | .02 |
| Total gross costs for Part D prescription drugs | 5849 (9122) | 5046 (8199) | −803 (−1522 to −83) | −13.7 (−26.0 to −1.4) | .03 |
| Total beneficiary out-of-pocket payments for Part D prescription drugs | 1536 (1891) | 1353 (2197) | −196 (−383 to −8) | −12.7 (−24.9 to −0.5) | .04 |
| Total Medicare spending | 15,096 (21,821) | 15,005 (23,522) | −133 (−1946 to 1681) | −0.9 (−12.9 to 11.1) | .89 |

Abbreviation: FFS, fee-for-service.

* Outcomes include annual measures of health care use and spending. Means are calculated across person-years. The estimation sample for spending measures included 3254 person-years from 2012 to 2015 with observed FFS Medicare enrollment (Parts A and B) and Part D prescription drug coverage. The estimation sample for hospital and emergency department use included 2327 person-years from 2012 to 2014 with observed FFS Medicare enrollment (Parts A and B) and Part D prescription drug coverage.

b Reports adjusted difference and confidence interval divided by the control mean.

c Spending results expressed in constant 2015 dollars.
important for successfully improving chronic disease management and reducing health care use and spending, but spending reductions may not persist beyond the intervention period.21

While our analysis found that reductions in prescription drug spending persisted beyond the trial period, the differences became statistically insignificant over time. In addition, the benefits in terms of reduced hospitalizations during the intervention did not persist beyond the intervention period, although hospitalizations were measured during the trial using validated self-reports and medical record reviews rather than Medicare data.21 This result may imply that the benefits of lifestyle intervention diminish over time, particularly as the patient cohort ages and faces other health risks. Extending interventions may be a potential approach to achieve persistent effects of ILI; however, more evidence is needed to determine whether this is an effective strategy to reduce long-term health care use and spending. Alternatively, there is evidence that the Look AHEAD ILI was associated with reduced bone mineral density and increased the risk of frailty fractures.31 More work is needed to investigate whether such outcomes may have increased hospitalizations, potentially offsetting the other clinical benefits of Look AHEAD.

Given that microvascular and macrovascular complications of diabetes continue to develop 15 to 25 years after diagnosis,32 the full benefits of the ILI in terms of reduced health care use and spending may have yet to be observed. In addition, starting in 2015, clinical guidelines began favoring new, more expensive drugs as second-line treatments for type 2 diabetes, including sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide 1 agonists.33 To the extent that the ILI and control groups had varying needs for these new agents, this may also have affected differences in prescription drug costs and total health care spending after our sample period. Finally, although the costs of the ILI may not have been offset by other health care savings during and after the

Figure 3. Adjusted Health Care Use and Spending by Intervention Status

Each point represents the utilization outcome in each year separately for intervention and control participants, adjusting for baseline participant characteristics and study site. Spending measures presented in 2015 dollars. Error bars indicate 95% CIs.
intervention, the considerable clinical and functional benefits of ILI during and after the intervention period may have been worth the costs. Formal cost-effectiveness analysis is necessary to weigh the costs and benefits of the ILI.

**Limitations**

Our study had several limitations. First, because the questions about data linkage manifested after the study was under way, we were only able to link 54% of the original cohort to Medicare records. To the extent that linked ILI participants differed from linked control participants along unobserved attributes that were correlated with long-term health care use, such imbalance could introduce bias into our results. However, we were able to link a nearly identical percentage of ILI and control participants to Medicare data (54% in each group), the linked participants were similar to the original cohort along observed characteristics, the linked intervention and control groups were balanced across observed characteristics, and most importantly, the intervention had similar effects on body weight and HbA1c for linked participants as the original cohort.

Second, we were not able to observe all outcomes for all linked participants. In particular, we only observed total Medicare spending among fee-for-service Medicare enrollees with Part D prescription drug coverage. However, we did not observe differential enrollment by study arm, suggesting that this did not bias our estimates.

Third, we were only able to observe health care use recorded in the Medicare program. One of the Look AHEAD trials’ clinic sites included a Veterans Health Administration facility. Individuals with both Veterans and Medicare coverage may have received care at Veterans Health Administration facilities that did not appear in Medicare claims. Only approximately 5% of the sample came from this site, and our results were unchanged removing this site from the sample.

Fourth, the Look AHEAD trial recruited volunteers with type 2 diabetes who could complete a fitness test and were motivated to participate in the trial. Thus, the outcomes associated with ILI could differ in a broader population with type 2 diabetes.

**Conclusions**

This ancillary study found that a randomized clinical trial of an ILI was not associated with reduced total Medicare spending in the years immediately following the intervention. These results suggest that ILIs may need to be sustained for reductions in health care costs to persist. However, some of the benefits of the trial may have yet to be observed, implying the importance of continued evaluation.

**ARTICLE INFORMATION**

Accepted for Publication: September 10, 2020.

Published: November 24, 2020. doi:10.1001/jamanetworkopen.2020.25488

Open Access: This is an open access article distributed under the terms of the CC-BY License. © 2020 Huckfeldt PJ et al. JAMA Network Open.

Corresponding Author: Peter J. Huckfeldt, PhD, Division of Health Policy and Management, University of Minnesota School of Public Health, 420 Delaware St SE, MMC 729, Minneapolis, MN 55455 (huckfeldt@umn.edu).

Author Affiliations: Division of Health Policy and Management, University of Minnesota School of Public Health, Minneapolis (Huckfeldt, Frenier); Department of Biostatistics and Data Science, Wake Forest School of Medicine, Winston-Salem, North Carolina (Pajewski, Espeland, Casanova); Keck School of Medicine of the University of Southern California, Los Angeles (Peters); Columbia University, New York, New York (Pi-Sunyer); George Mason University, Fairfax, Virginia (Cheskin); Leonard D. Schaeffer Center for Health Policy and Economics, University of Southern California, Los Angeles (Goldman); School of Pharmacy, University of Southern California, Los Angeles (Goldman); Price School of Public Policy, University of Southern California, Los Angeles (Goldman).

Author Contributions: Dr Huckfeldt and Mr Frenier had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.
Concept and design: Huckfeldt, Pajewski, Espeland, Pi-Sunyer, Goldman.

Acquisition, analysis, or interpretation of data: All authors.

Drafting of the manuscript: Huckfeldt, Espeland, Goldman.

Critical revision of the manuscript for important intellectual content: All authors.

Statistical analysis: Huckfeldt, Frenier, Goldman.

Obtained funding: Huckfeldt, Pajewski, Espeland, Pi-Sunyer, Goldman.

Administrative, technical, or material support: Huckfeldt, Espeland, Pi-Sunyer, Goldman.

Supervision: Huckfeldt, Pajewski, Espeland, Pi-Sunyer, Goldman.

Conflict of Interest Disclosures: Dr. Huckfeldt reported receiving research funding from the Florida Medical Malpractice Joint Underwriting Association and serving as an adjunct economist at the RAND Corporation and as a consultant for the Urban Institute outside the submitted work. Dr. Frenier reported receiving grants from Robert Wood Johnson Foundation outside the submitted work. Dr. Espeland reported receiving personal fees from Boehringer-Ingelheim Pharma outside the submitted work. Dr. Peters reported serving on advisory boards for Eli Lilly and Company, Mankind, Abbott Diabetes Care, Merck, BioRad, NovoNordisk, and Medscape; receiving research funding from Dexcom, vTv Therapeutics, and Abbott Diabetes Care; and owning stock options from Omada Health, Stability Health, Pendulum Therapeutics, and Livongo. Dr. Goldman reported receiving research support from Blue Cross Blue Shield of Arizona, Bristol Myers Squibb, Cedars-Sinai Health System, Edwards Lifesciences, Gates Ventures, Genentech, Gilead Sciences, Johnson and Johnson, Kaiser Family Foundation, National Institutes of Health, Novartis, Pfizer, Roche, and Walgreens Boots Alliance; speaker fees or honoraria from Amsen, The Aspen Institute, and Celgene; consulting income from ACADIA Pharmaceuticals, Biogen, GGRAIL, and Precision Medicine Group; and owning equity in Precision Medicine Group.

Funding/Support: This research was funded by grant No. R01 DK107552 from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) as an ancillary study to the Look AHEAD trial, which was funded by the National Institutes of Health (NIH) through cooperative agreements with the NIDDKD (grants DK57136, DK57149, DK56990, DK57177, DK57171, DK57151, DK57182, DK57131, DK57002, DK57078, DK57154, DK57178, DK57219, DK57008, DK57135, and DK56992). Additional funding was provided by the National Heart, Lung, and Blood Institute, National Institute of Nursing Research, National Center on Minority Health and Health Disparities, NIH Office of Research on Women’s Health, and the Centers for Disease Control and Prevention.

Role of the Funder/Sponsor: The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

Data Sharing Statement: See Supplement 3.

REFERENCES

1. American Diabetes Association. Economic costs of diabetes in the U.S. in 2017. Diabetes Care. 2018;41(5):917-928. doi:10.2337/dc18-0007

2. Gruss SM, Nhim K, Gregg E, Bell M, Luman E, Albright A. Public health approaches to type 2 diabetes prevention: the US National Diabetes Prevention Program and beyond. Curr Diab Rep. 2019;19(9):78. doi:10.1007/s11892-019-1200-z

3. Anderson JW, Kendall CWC, Jenkins DJA. Importance of weight management in type 2 diabetes: review with meta-analysis of clinical studies. J Am Coll Nutr. 2003;22(5):331-339. doi:10.1080/07315724.2003.10719316

4. American Diabetes Association. 5. Lifestyle management: standards of medical care in diabetes-2019. Diabetes Care. 2019;42(suppl 1):S46-S60. doi:10.2337/dc19-S005

5. Community Preventive Services Task Force. Diabetes prevention and control: intensive lifestyle interventions for patients with type 2 diabetes. Ratified October 2016. Accessed October 19, 2020. https://www.thecommunityguide.org/sites/default/files/assets/Diabetes-Lifestyle-Interventions.pdf

6. Huang X-L, Pan J-H, Chen D, Chen J, Chen F, Hu TT. Efficacy of lifestyle interventions in patients with type 2 diabetes: a systematic review and meta-analysis. Eur J Intern Med. 2016;27:37-47. doi:10.1016/j.ejim.2015.11.016

7. Knowler WC, Barrett-Connor E, Fowler SE, et al; Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346(6):393-403. doi:10.1056/NEJMoa012512

8. Wing RR, Bolin P, Brancati FL, et al; Look AHEAD Research Group. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med. 2013;369(2):145-154. doi:10.1056/NEJMoa1212914
9. Centers for Medicare and Medicaid Services. Medicare Diabetes Prevention Program (MDPP) expanded model. Updated August 2020. Accessed October 19, 2020. https://innovation.cms.gov/innovation-models/medicare-diabetes-prevention-program
10. Mattke S, Liu H, Caloyeras J, et al. Workplace Wellness Programs Study: Final Report. RAND Health Quarterly. Accessed October 19, 2020. https://www.rand.org/pubs/research_reports/RR254.html
11. Bojadzievski T, Gabbay RA. Patient-centered medical home and diabetes. Diabetes Care. 2011;34(4):1047-1053. doi:10.2337/dc10-1671
12. Hernan WH, Brandle M, Zhang P, et al; Diabetes Prevention Program Research Group. Costs associated with the primary prevention of type 2 diabetes mellitus in the diabetes prevention program. Diabetes Care. 2003;26(1):36-47. doi:10.2337/diacare.26.1.36
13. Rushing J, Wing R, Wadden TA, et al; Look AHEAD Research Group. Cost of intervention delivery in a lifestyle weight loss trial in type 2 diabetes: results from the Look AHEAD clinical trial. Obes Sci Pract. 2017;3(1):15-24. doi:10.1002/osp4.92
14. Jha AK. Population health management: saving lives and saving money? JAMA. 2019;322(5):390-391. doi:10.1001/jama.2019.10568
15. Li R, Zhang P, Barker LE, Chowdhury FM, Zhang X. Cost-effectiveness of interventions to prevent and control diabetes mellitus: a systematic review. Diabetes Care. 2010;33(8):1872-1894. doi:10.2337/dc10-0843
16. Nuckols TK, Keeler E, Anderson LJ, et al. Economic evaluation of quality improvement interventions designed to improve glycemic control in diabetes: a systematic review and weighted regression analysis. Diabetes Care. 2018;41(4):985-993. doi:10.2337/dc17-1495
17. Wing RR; Look AHEAD Research Group. Long-term effects of a lifestyle intervention on weight and cardiovascular risk factors in individuals with type 2 diabetes mellitus: four-year results of the Look AHEAD trial. Arch Intern Med. 2010;170(17):1566-1575.
18. Rubin RR, Wadden TA, Bahson JL., et al; Look AHEAD Research Group. Impact of intensive lifestyle intervention on depression and health-related quality of life in type 2 diabetes: the Look AHEAD Trial. Diabetes Care. 2014;37(6):1544-1553. doi:10.2337/dc13-1928
19. Gregg EW, Chen H, Wagenknecht LE, et al; Look AHEAD Research Group. Association of an intensive lifestyle intervention with remission of type 2 diabetes. JAMA. 2012;308(23):2489-2496. doi:10.1001/jama.2012.67929
20. Houston DK, Leng X, Bray GA, et al; Action for Health In Diabetes (Look AHEAD) Movement and Memory Ancillary Study Research Group. A long-term intensive lifestyle intervention and physical function: the look AHEAD Movement and Memory Study. Obesity (Silver Spring). 2015;23(1):77-84. doi:10.1002/oby.20944
21. Espeland MA, Glick HA, Bertoni A, et al; Look AHEAD Research Group. Impact of an intensive lifestyle intervention on use and cost of medical services among overweight and obese adults with type 2 diabetes: the action for health in diabetes. Diabetes Care. 2014;37(9):2548-2556. doi:10.2337/dc14-0093
22. Landon BE, Zaslavsky AM, Saunders R, Pawlson LG, Newhouse JP, Ayanian JZ. A comparison of relative resource use and quality in Medicare Advantage health plans versus traditional Medicare. Am J Manag Care. 2015;21(8):559-566.
23. Research Data Assistance Center. Part D total prescription drug costs. Accessed August 29, 2020. https://www.resdac.org/cms-data/variables/part-d-total-prescription-costs
24. Social Security Administration. Medicare information. Accessed October 19, 2020. https://www.ssa.gov/disabilityresearch/what/medicare.htm
25. Deb P, Norton EC. Modeling health care expenditures and use. Annu Rev Public Health. 2018;39:489-505. doi:10.1146/annurev-publhealth-040617-013517
26. Chao AM, Wadden TA, Berkowitz RI, et al; Look AHEAD Research Group. Weight change 2 years after termination of the intensive lifestyle intervention in the Look AHEAD Study. Obesity (Silver Spring). 2020;28(5):893-901. doi:10.1002/oby.22769
27. Wagner EH, Sandhu N, Newton KM, McCulloch DK, Ramsey SD, Grothaus LC. Effect of improved glycemic control on health care costs and utilization. JAMA. 2001;285(2):182-189. doi:10.1001/jama.285.2.182
28. Cawley J, Meyerhoefer C, Bierer A, Hammer M, Wintfeld N. Savings in Medical expenditures associated with reductions in body mass index among US adults with obesity, by diabetes status. Pharmacoeconomics. 2015;33(7):707-722. doi:10.1007/s40273-014-0230-2
29. Song Z, Baicker K. Effect of a workplace wellness program on employee health and economic outcomes: a randomized clinical trial. JAMA. 2019;321(15):1491-1501. doi:10.1001/jama.2019.3307
30. Jones D, Molitor D, Reif J. What do workplace wellness programs do: evidence from the Illinois Workplace Wellness Study. Q J Econ. 2019;134(4):1747-1791. doi:10.1093/qje/qjz023

31. Johnson KC, Bray GA, Cheskin LJ, et al; Look AHEAD Study Group. The effect of intentional weight loss on fracture risk in persons with diabetes: results from the Look AHEAD randomized clinical trial. J Bone Miner Res. 2017;32(11):2278-2287. doi:10.1002/jbmr.3214

32. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359(15):1577-1589. doi:10.1056/NEJMoa0806470

33. Gurgle HE, White K, McAdam-Marx C. SGLT2 inhibitors or GLP-1 receptor agonists as second-line therapy in type 2 diabetes: patient selection and perspectives. Vasc Health Risk Manag. 2016;12:239-249.

SUPPLEMENT 1.

Manuscript Proposal

SUPPLEMENT 2.

eTable 1. Sample Sizes by Analytic Sample
eTable 2. Baseline Characteristics of Full Sample and Linked Participants
eTable 3. Health Care Use and Spending by Intervention Group, 2012 to 2015
eAppendix. Supplementary Methods and Results

SUPPLEMENT 3.

Data Sharing Statement